The Effectiveness of Creatine Treatment for Parkinson's Disease: an Updated Meta-analysis of Randomized Controlled Trials

Overview

Journal BMC Neurol

Publisher Biomed Central

Specialty Neurology

Date 2017 Jun 5

PMID 28577542

Citations 10

Authors

Jia-Jie Mo

Lin-Ying Liu

Wei-Bin Peng

Jie Rao

Zhou Liu

Li-Li Cui

Affiliations

Soon will be listed here.

Abstract

Background: The effectiveness of creatine in treating Parkinson's disease (PD) has not been conclusively determined. Therefore, we performed a meta-analysis to address this issue.

Methods: The Cochrane Central Register of Controlled Trials, PUBMED, EMBASE, and other databases were searched, and outcomes measured by the Total Unified Parkinson's Disease Rating Scale (UPDRS) and the Schwab & England Scale were analyzed.

Results: Five randomized controlled trials (RCTs) were selected, and 1339 participants were included in the analysis. There were no significant differences between the control and treatment groups in the total, mental, activities of daily living (ADL), or motor UPDRS scores, but an improvement in Schwab & England Scale scores was observed.

Conclusions: Creatine has no observed benefit in PD patients, although more correlated studies are still needed.

Citing Articles

Oxidative Stress and Antioxidants in Neurodegenerative Disorders.

Olufunmilayo E, Gerke-Duncan M, Holsinger R Antioxidants (Basel). 2023; 12(2).

PMID: 36830075 PMC: 9952099. DOI: 10.3390/antiox12020517.

Metabolomics as a Crucial Tool to Develop New Therapeutic Strategies for Neurodegenerative Diseases.

Lanznaster D, Dingeo G, Samey R, Emond P, Blasco H Metabolites. 2022; 12(9).

PMID: 36144268 PMC: 9503806. DOI: 10.3390/metabo12090864.

Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease.

Paul Choudhury S, Bano S, Sen S, Suchal K, Kumar S, Nikolajeff F NPJ Parkinsons Dis. 2022; 8(1):66.

PMID: 35650269 PMC: 9160246. DOI: 10.1038/s41531-022-00324-9.

Parkinson disease-associated cognitive impairment.

Aarsland D, Batzu L, Halliday G, Geurtsen G, Ballard C, Chaudhuri K Nat Rev Dis Primers. 2021; 7(1):47.

PMID: 34210995 DOI: 10.1038/s41572-021-00280-3.

Promising drug targets and associated therapeutic interventions in Parkinson's disease.

Rai S, Singh P, Varshney R, Chaturvedi V, Vamanu E, Singh M Neural Regen Res. 2021; 16(9):1730-1739.

PMID: 33510062 PMC: 8328771. DOI: 10.4103/1673-5374.306066.

References

. A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol. 2008; 31(3):141-50. PMC: 4372145. DOI: 10.1097/WNF.0b013e3181342f32. View

Ostojic S, Ostojic J, Drid P, Vranes M . Guanidinoacetic acid versus creatine for improved brain and muscle creatine levels: a superiority pilot trial in healthy men. Appl Physiol Nutr Metab. 2016; 41(9):1005-7. DOI: 10.1139/apnm-2016-0178. View

Bloom M . NIH announces phase III clinical trial of creatine for Parkinson's disease. Consult Pharm. 2007; 22(5):378. View

Klein A, Ferrante R . The neuroprotective role of creatine. Subcell Biochem. 2008; 46:205-43. DOI: 10.1007/978-1-4020-6486-9_11. View

LeWitt P . Clinical trials of neuroprotection for Parkinson's disease. Neurology. 2004; 63(7 Suppl 2):S23-31. DOI: 10.1212/wnl.63.7_suppl_2.s23. View

Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M . Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006; 67(7):1262-4. DOI: 10.1212/01.wnl.0000238518.34389.12. View

Yagi K, Tanabe H . [The elevation of serum creatine kinase in the course of Parkinson disease.--in relation to malignant syndrome]. Rinsho Shinkeigaku. 1996; 36(8):935-9. View

Wyss M, Schulze A . Health implications of creatine: can oral creatine supplementation protect against neurological and atherosclerotic disease?. Neuroscience. 2002; 112(2):243-60. DOI: 10.1016/s0306-4522(02)00088-x. View

Bereket-Yucel S . Creatine supplementation alters homocysteine level in resistance trained men. J Sports Med Phys Fitness. 2015; 55(4):313-9. View

10.

Lawler J, Barnes W, Wu G, Song W, Demaree S . Direct antioxidant properties of creatine. Biochem Biophys Res Commun. 2002; 290(1):47-52. DOI: 10.1006/bbrc.2001.6164. View

11.

. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006; 66(5):664-71. DOI: 10.1212/01.wnl.0000201252.57661.e1. View

12.

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

13.

Puri V, Chaudhry N, Goel S, Gulati P, Nehru R, Chowdhury D . Vitamin B12 deficiency: a clinical and electrophysiological profile. Electromyogr Clin Neurophysiol. 2005; 45(5):273-84. View

14.

Comi C, Magistrelli L, Oggioni G, Carecchio M, Fleetwood T, Cantello R . Peripheral nervous system involvement in Parkinson's disease: evidence and controversies. Parkinsonism Relat Disord. 2014; 20(12):1329-34. DOI: 10.1016/j.parkreldis.2014.10.010. View

15.

Simon D, Wu C, Tilley B, Wills A, Aminoff M, Bainbridge J . Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine. Clin Neuropharmacol. 2015; 38(5):163-9. PMC: 4573899. DOI: 10.1097/WNF.0000000000000102. View

16.

Stork C, Renshaw P . Mitochondrial dysfunction in bipolar disorder: evidence from magnetic resonance spectroscopy research. Mol Psychiatry. 2005; 10(10):900-19. DOI: 10.1038/sj.mp.4001711. View

17.

Hass C, Collins M, Juncos J . Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007; 21(2):107-15. DOI: 10.1177/1545968306293449. View

18.

Joncquel-Chevalier Curt M, Voicu P, Fontaine M, Dessein A, Porchet N, Mention-Mulliez K . Creatine biosynthesis and transport in health and disease. Biochimie. 2015; 119:146-65. DOI: 10.1016/j.biochi.2015.10.022. View

19.

Allen P . Creatine metabolism and psychiatric disorders: Does creatine supplementation have therapeutic value?. Neurosci Biobehav Rev. 2012; 36(5):1442-62. PMC: 3340488. DOI: 10.1016/j.neubiorev.2012.03.005. View

20.

Lee A, Gilbert R . Epidemiology of Parkinson Disease. Neurol Clin. 2016; 34(4):955-965. DOI: 10.1016/j.ncl.2016.06.012. View